WASHINGTON, D.C.-There's new evidence that ready access to medications can reduce overall healthcare spending. A study of California Medicare beneficiaries who had a $1,000 annual cap on drug coverage finds that they spent less on drugs, but more on emergency care and hospitalizations. And they had a higher death rate compared with seniors with unlimited drug coverage.
WASHINGTON, D.C.-There's new evidence that ready access to medications can reduce overall healthcare spending. A study of California Medicare beneficiaries who had a $1,000 annual cap on drug coverage finds that they spent less on drugs, but more on emergency care and hospitalizations. And they had a higher death rate compared with seniors with unlimited drug coverage.
The study led by researchers at Kaiser Permanente, Oakland, Calif., and published in the June 1, 2006, New England Journal of Medicine, reports that patients with limited drug benefits were more likely to reduce their use of drugs to treat chronic conditions, such as diabetes, high blood pressure and high cholesterol. The study concludes that the savings in drug costs from the cap were offset by increases in the costs of hospitalization and emergency care, as well as unfavorable clinical outcomes.
The results point to the importance of the new Medicare drug benefit in enhancing healthcare for seniors. But the study also supports those who object to the design of the Medicare program, which requires most seniors to pick up drug costs after they hit a $2,250 coverage limit.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More